Abstract
Background: Previous studies have suggested that the presence of visceral metastasis is a parameter useful in predicting the treatment efficacy of fulvestrant in patients with advanced breast cancer. Patients and Methods: We retrospectively examined the association between treatment efficacy and presence of visceral metastasis in 75 patients with hormone receptor-positive recurrent breast cancer who were treated with fulvestrant or no more than five lines of other endocrine monotherapy after recurrence. Results: Nineteen patients received fulvestrant, 10 of whom had visceral metastasis. The median time to progression was 4 months for the overall study population; it was significantly longer for patients with non-visceral metastasis (5.4 months; 95% confidence interval=3.7-11.2 months) than for those with visceral metastasis (3.3 months; 95% confidence interval, 0.4-5.3 months; p=0.01). No differences in time to progression were found between the groups of patients with visceral metastasis and non-visceral metastasis who underwent other endocrine therapies. Conclusion: Fulvestrant is more effective for patients with non-visceral metastasis of recurrent breast cancer with than for those with visceral metastasis.
| Original language | English |
|---|---|
| Pages (from-to) | 1579-1584 |
| Number of pages | 6 |
| Journal | Anticancer research |
| Volume | 38 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2018 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Impact of visceral metastasis on efficacy of fulvestrant in patients with hormone receptor-positive recurrent breast cancer. / Koi, Yumiko; Koga, Chinami; Akiyoshi, Sayuri; Masuda, Takanobu; Ijichi, Hideki; Nakamura, Yoshiaki; Ishida, Mayumi; Ohno, Shinji; Tokunaga, Eriko.
In: Anticancer research, Vol. 38, No. 3, 03.2018, p. 1579-1584.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of visceral metastasis on efficacy of fulvestrant in patients with hormone receptor-positive recurrent breast cancer
AU - Koi, Yumiko
AU - Koga, Chinami
AU - Akiyoshi, Sayuri
AU - Masuda, Takanobu
AU - Ijichi, Hideki
AU - Nakamura, Yoshiaki
AU - Ishida, Mayumi
AU - Ohno, Shinji
AU - Tokunaga, Eriko
PY - 2018/3
Y1 - 2018/3
N2 - Background: Previous studies have suggested that the presence of visceral metastasis is a parameter useful in predicting the treatment efficacy of fulvestrant in patients with advanced breast cancer. Patients and Methods: We retrospectively examined the association between treatment efficacy and presence of visceral metastasis in 75 patients with hormone receptor-positive recurrent breast cancer who were treated with fulvestrant or no more than five lines of other endocrine monotherapy after recurrence. Results: Nineteen patients received fulvestrant, 10 of whom had visceral metastasis. The median time to progression was 4 months for the overall study population; it was significantly longer for patients with non-visceral metastasis (5.4 months; 95% confidence interval=3.7-11.2 months) than for those with visceral metastasis (3.3 months; 95% confidence interval, 0.4-5.3 months; p=0.01). No differences in time to progression were found between the groups of patients with visceral metastasis and non-visceral metastasis who underwent other endocrine therapies. Conclusion: Fulvestrant is more effective for patients with non-visceral metastasis of recurrent breast cancer with than for those with visceral metastasis.
AB - Background: Previous studies have suggested that the presence of visceral metastasis is a parameter useful in predicting the treatment efficacy of fulvestrant in patients with advanced breast cancer. Patients and Methods: We retrospectively examined the association between treatment efficacy and presence of visceral metastasis in 75 patients with hormone receptor-positive recurrent breast cancer who were treated with fulvestrant or no more than five lines of other endocrine monotherapy after recurrence. Results: Nineteen patients received fulvestrant, 10 of whom had visceral metastasis. The median time to progression was 4 months for the overall study population; it was significantly longer for patients with non-visceral metastasis (5.4 months; 95% confidence interval=3.7-11.2 months) than for those with visceral metastasis (3.3 months; 95% confidence interval, 0.4-5.3 months; p=0.01). No differences in time to progression were found between the groups of patients with visceral metastasis and non-visceral metastasis who underwent other endocrine therapies. Conclusion: Fulvestrant is more effective for patients with non-visceral metastasis of recurrent breast cancer with than for those with visceral metastasis.
UR - http://www.scopus.com/inward/record.url?scp=85043428481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043428481&partnerID=8YFLogxK
U2 - 10.21873/anticanres.12387
DO - 10.21873/anticanres.12387
M3 - Article
C2 - 29491088
AN - SCOPUS:85043428481
VL - 38
SP - 1579
EP - 1584
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 3
ER -